spacer
home > epc > spring 2002 > uk and european biotechs - partnering for profit
PUBLICATIONS
European Pharmaceutical Contractor

UK and European Biotechs - Partnering for Profit

The British biotech sector may be providing many globally-important technological answers, but it is also continuing to question how best to find and work with others in both discovery and development. No biotechnology company, however big, can completely go it alone. Getting together with US partners has often been the route for UK companies but as this article emphasises, there are wonderful opportunities in Europe and it is just as easy to cross the Channel as the Atlantic.

Whether their goal is technological, commercial, manufacturing or marketing know-how, partnerships are proving invaluable in the battle for biotech survival and added value. With an increasingly complex market, and with the time to achieve critical mass and gain entry to market continually shortening, I think it is inevitable that the search for appropriate alliances will continue to rise inexorably up the agenda. Despite its many strengths, this search is especially important for the UK biotech sector. While we in the UK are deservedly renowned for the innovative excellence of our basic ideas, it has also been known for others to get these ideas to market first and reap the rewards. Partnerships can help us to avoid this scenario.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Philip Oliver, International Technology Promoter, Life Sciences - Europe

The first International Technology Promoter with a specific European life sciences focus, Philip Oliver calls on his wide-ranging involvement with the biotechnology, pharmaceutical and related industries to promote partnerships with the UK. As a biotech business development specialist with 12 years' experience of working in the US and Europe, Philip has expertise in the areas of environment, health, safety, quality management, project management and toxicology.

Before joining Pera, Philip was European Manager of Business Development for a leading pharmaceutical and biotechnology research organisation. He has also held posts in the chemical and oil industry. Philip has a BSc with Associateship of the Royal College of Science from Imperial College, London and is involved with the biotech special interest group of the Drug Information Association.

spacer
Philip Oliver
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement